• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Virafin from Zydus Cadila priced at Rs 11,995 per dose

expresspharmaMay 12, 2021

Tag: Zydus Cadila , Virafin , COVID-19 , DCGI

As per reports, Zydus Cadila has fixed the price of Virafin, a medicine that has received EUA for COVID-19 treatment, at Rs 11,995 per dose. Reportedly, the company has commenced dispatching the drug which can reportedly reduce oxygen support in COVID-19 patients.

Virafin from Zydus Cadila priced at Rs 11,995 per dose

The Drug Controller General of India (DCGI) gave emergency authorisation for restricted use to Virafin, a single-use therapy, on April 23.

Technically known as Pegylated Interferon alpha-2b, it is used to treat moderate infection of COVID-19. The company has said, “91.15 per cent of patients treated with PegIFN were RT-PCR negative by day 7.”

Previous:Woodstock Sterile Solutions Names Oliver Vogt as VP and General Manager

Next:Kejriwal asks PM to share vaccine formula with pharma firms to ramp up manufacturing

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Virafin from Zydus Cadila priced at Rs 11,995 per dose | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Real Time Multiplex RT-PCR Kit (for COVID-19)

Real Time Multiplex RT-PCR Kit (for COVID-19)
SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)

SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins
CEFIXIME cephalosporins

CEFIXIME cephalosporins
CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service